Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction

Patients with coronary artery disease remain at increased risk of recurrent life-threatening cardiovascular events even after adequate guideline-based treatment of conventional risk factors, including blood lipid levels. Inflammation is a critical pathway in the pathogenesis of atherosclerosis and i...

Descripción completa

Detalles Bibliográficos
Autores principales: Prescott, Eva, Pernow, John, Saraste, Antti, Åkerblom, Axel, Angerås, Oskar, Erlinge, David, Grove, Erik L., Hedman, Marja, Jensen, Lisette O., Svedlund, Sara, Kjaer, Magnus, Lagerström-Fermér, Maria, Gan, Li-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451793/
https://www.ncbi.nlm.nih.gov/pubmed/32875138
http://dx.doi.org/10.1016/j.conctc.2020.100629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7451793/
https://www.ncbi.nlm.nih.gov/pubmed/32875138
http://dx.doi.org/10.1016/j.conctc.2020.100629

Ejemplares similares